Zhou X, Besse A, Peter J, Steinhardt MJ, Vogt C, Nerreter S, Teufel E, Stanojkovska E, Xiao X, Hornburger H, Haertle L, Lopez MM, Munawar U, Riedel A, Han S, Maurits E, Overkleeft HS, Florea B, Einsele H, Kortüm KM, Driessen C, Besse L, Rasche L. High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex. Haematologica 2023;108(6):1628-1639; https://doi.org/10.3324/haematol.2022.282225.